Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric asciminib dose and safety study in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia
NL-OMON54333Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of asciminib in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive chronic myeloid leukemia (2 arms), sponsored by Novartis. Primary endpoint: Pharmacokinetic profile of asciminib. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)Philadelphia chromosome-positive chronic myeloid leukemia
Beyond the preview
Go deeper on NL-OMON54333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54333.